Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UC CIMZIA
- 30 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 30 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.